Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 11, 2020
Daily News
May 11, 2020
- Mylan EPD Curbing Nesp Biosimilar Supplies amid Big Demand
May 11, 2020
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Univ. of Tokyo Starts Testing Avigan Plus Futhan for COVID-19
May 11, 2020
- Chuikyo OKs Special Mixed Care Scheme for Veklury
May 11, 2020
- Jitsubo Licenses Peptide Manufacturing Technology to Bachem
May 11, 2020
- Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
- Chugai Begins Joint Research with Singapore Agency on Novel Antibody Drug for COVID-19
May 11, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Astellas to Carry on Teleworking through End of May
May 11, 2020
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…